Tadaaki Yamada

6.2k citations

212 papers · 3.8k indexed · h-index 34

Oncology top 1%
Pulmonary and Respiratory Medicine top 1%
Molecular Biology top 5%
Cancer Research top 5%
Surgery top 10%

Co-authors: Seiji Yano Shinji Takeuchi Koichi Takayama Kunio Matsumoto Junji Uchino Yoshiko KanekoWei WangYasuhiko Nishioka
Topics: Lung Cancer Treatments and Mutations (102 papers)Lung Cancer Research Studies (59 papers)Cancer Immunotherapy and Biomarkers (38 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Gastroenterology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaGastroenterology
Partner nations: Japan United States China

In The Last Decade

Tadaaki Yamada

204 papers receiving 3.7k citations

Peers

Countries citing papers authored by Tadaaki Yamada

Since Specialization

Citations

This map shows the geographic impact of Tadaaki Yamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadaaki Yamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadaaki Yamada more than expected).

Fields of papers citing papers by Tadaaki Yamada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadaaki Yamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadaaki Yamada. The network helps show where Tadaaki Yamada may publish in the future.

Co-authorship network of co-authors of Tadaaki Yamada

This figure shows the co-authorship network connecting the top 25 collaborators of Tadaaki Yamada. A scholar is included among the top collaborators of Tadaaki Yamada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadaaki Yamada. Tadaaki Yamada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma 2024 ·Cancer Genomics & Proteomics ·(unknown),(unknown),Tadaaki Yamada,Yuki Toda,Shigekuni Hosogi,(unknown)	3
2	Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% 2024 ·JTO Clinical and Research Reports ·Yoshihito Kogure,Hiroya Hashimoto,Haruko Daga,Yasushi Fukuda,Akihiro Bessho,Tadaaki Yamada,Yukihiro Toi,Tomoki Kimura,Hiroshige Yoshioka,Koichi Azuma,Naoki Furuya,Yasutaka Fukui,Akiko Saito,Nobuyuki Yamamoto,Hideo Saka,Masashi Kondo	0
3	The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review 2023 ·Translational Lung Cancer Research ·(unknown),Tadaaki Yamada,Koichi Takayama	20
4	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice 2019 ·Molecular Cancer Therapeutics ·Rong Wang,Tadaaki Yamada,Sachiko Arai,Koji Fukuda,Hirokazu Taniguchi,Azusa Tanimoto,Akihiro Nishiyama,Shinji Takeuchi,Kaname Yamashita,(unknown),Junji Matsui,Naoyoshi Onoda,Eishu Hirata,Shu Taira,Seiji Yano	20
5	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model 2018 ·Clinical Cancer Research ·Akihiro Nishiyama,Tadaaki Yamada,Kenji Kita,Rong Wang,Sachiko Arai,Koji Fukuda,Azusa Tanimoto,Shinji Takeuchi,Shoichiro Tange,Atsushi Tajima,Noritaka Furuya,Takayoshi Kinoshita,Seiji Yano	22
6	Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study 2018 ·Pain ·Lynn R. Webster,Srinivas Nalamachu,Bart Morlion,(unknown),(unknown),Tadaaki Yamada,Juan Camilo Arjona Ferreira	68
7	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations 2017 ·Molecular Cancer Therapeutics ·Tadaaki Yamada,Joseph M. Amann,Azusa Tanimoto,Hirokazu Taniguchi,Takehito Shukuya,Cynthia Timmers,Seiji Yano,Konstantin Shilo,David P. Carbone	31
8	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer 2017 ·Molecular Cancer Therapeutics ·Shigeki Nanjo,Sachiko Arai,Wei Wang,Shinji Takeuchi,Tadaaki Yamada,Akito Hata,Nobuyuki Katakami,Yasunori Okada,Seiji Yano	47
9	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer 2016 ·Clinical Cancer Research ·Azusa Tanimoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Tadaaki Yamada,Xavier Roca,S. Tiong Ong,Seiji Yano	71
10	A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain 2016 ·Pain Medicine ·Lynn R. Webster,Tadaaki Yamada,Juan Camilo Arjona Ferreira	51
11	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma 2016 ·Cancer Research ·Jacob M. Kaufman,Tadaaki Yamada,Kyungho Park,Cynthia Timmers,Joseph M. Amann,David P. Carbone	19
12	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma 2015 ·Cancer Research ·Tadaaki Yamada,Joseph M. Amann,Koji Fukuda,Shinji Takeuchi,Naoya Fujita,Hisanori Uehara,Shotaro Iwakiri,Kazumi Itoi,Konstantin Shilo,Seiji Yano,David P. Carbone	17
13	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition 2013 ·Cancer Research ·Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano	136
14	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer 2012 ·Molecular Cancer Therapeutics ·Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Shigeki Nanjo,Daisuke Ishikawa,Takako Sano,Kenji Kita,Takahiro Nakamura,Kunio Matsumoto,Kenichi Suda,Tetsuya Mitsudomi,Yoshitaka Sekido,Toshimitsu Uenaka,Seiji Yano	74
15	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer 2012 ·Clinical Cancer Research ·Wei Wang,Qi Li,Shinji Takeuchi,Tadaaki Yamada,(unknown),Takahiro Nakamura,Kunio Matsumoto,Naofumi Mukaida,Yasuhiko Nishioka,Saburo Sone,Takayuki Nakagawa,Toshimitsu Uenaka,Seiji Yano	76
16	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells 2012 ·Clinical Cancer Research ·Tadaaki Yamada,Shinji Takeuchi,Junya Nakade,Kenji Kita,Takayuki Nakagawa,Shigeki Nanjo,Takahiro Nakamura,Kunio Matsumoto,Manabu Soda,Hiroyuki Mano,Toshimitsu Uenaka,Seiji Yano	93
17	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer 2011 ·Clinical Cancer Research ·Ivan Donev,Wei Wang,Tadaaki Yamada,Qi Li,Shinji Takeuchi,Kunio Matsumoto,Takao Yamori,Yasuhiko Nishioka,Saburo Sone,Seiji Yano	93
18	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor 2011 ·Molecular Cancer Therapeutics ·Hirokazu Ogino,Masaki Hanibuchi,Soji Kakiuchi,(unknown),Hisatsugu Goto,Kenji Ikuta,Tadaaki Yamada,Hisanori Uehara,Akihiko Tsuruoka,Toshimitsu Uenaka,Wei Wang,Qi Li,Shinji Takeuchi,Seiji Yano,Yasuhiko Nishioka,Saburo Sone	16
19	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR -T790M Mutant Lung Cancer 2009 ·Clinical Cancer Research ·Tadaaki Yamada,Kunio Matsumoto,Wei Wang,Qi Li,Yasuhiko Nishioka,Yoshitaka Sekido,Saburo Sone,Seiji Yano	85
20	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 2009 ·Clinical Cancer Research ·Wei Wang,Qi Li,Tadaaki Yamada,Kunio Matsumoto,Isao Matsumoto,Makoto Oda,Go Watanabe,(unknown),Yasuhiko Nishioka,Saburo Sone,Seiji Yano	231

About Tadaaki Yamada

Tadaaki Yamada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 212 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (59 papers) and Cancer Immunotherapy and Biomarkers (38 papers). The work is most often cited by research in Oncology (1.9k citations), Pulmonary and Respiratory Medicine (1.7k citations) and Gastroenterology (261 citations). Tadaaki Yamada has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Seiji Yano, Shinji Takeuchi, Koichi Takayama, Kunio Matsumoto, Junji Uchino, Yoshiko Kaneko, Wei Wang, Yasuhiko Nishioka, Yusuke Chihara and Saburo Sone. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact